Intravitreal VEGF Trap looking promising

Article

Interim results from a Phase I study suggest that intravitreal injection of VEGF Trap (Regeneron Pharmaceuticals) is a promising new approach for the treatment of exudative age-related macular degeneration, said Quan Dong Nguyen, MD, at the World Ophthalmology Congress.

Interim results from a Phase I study suggest that intravitreal injection of VEGF Trap (Regeneron Pharmaceuticals) is a promising new approach for the treatment of exudative age-related macular degeneration, said Quan Dong Nguyen, MD, at the World Ophthalmology Congress.

VEGF Trap is a fusion protein of key domains of VEGF receptors 1 and 2 as well as of placenta growth factor (PIGF) that is smaller than any known anti-VEGF antibodies, but has significantly higher binding affinity than those compounds. In addition, it has demonstrated efficacy in multiple preclinical cancer and ocular models.

The Phase I study of intravitreal administration enrolled 21 patients who received a single injection of VEGF Trap over the dose range of 0.05 to 4.0 mg. In follow-up available so far, there has been no systemic or ocular dose-limiting toxicity seen at the highest dose administered, while the treatment was associated with a rapid and substantial decrease in retinal thickness measured by optical coherence tomography that has persisted for at least 8 weeks.

"Additional studies will be performed to determine the optimal dose and dosing interval and another Phase I study will be randomizing patients to VEGF Trap or pegaptanib sodium (Macugen, OCI/Eyetech Pharmaceuticals). In addition, a Phase 2 trial is about to start that will examine three different doses of VEGF Trap administered at different frequencies," said Dr. Nguyen of the Wilmer Eye Institute/Johns Hopkins University in the United States.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.